Cefazolin/ertapenem/ticagrelorRebound thrombocytopenia, Off-label use and lack of efficacy: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1853卷 / 1期

关键词：

D O I：

10.1007/s40278-021-94982-0

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：116 / 116

相关论文

共 50 条

[1] AntineoplasticsDiarrhoea, off-label use and lack of efficacy: case report
Reactions Weekly, 2023, 1954 (1) : 49 - 49
[2] AntineoplasticsNeutropenia, off-label use and lack of efficacy: case report
Reactions Weekly, 2022, 1926 (1) : 69 - 69
[3] AntineoplasticsCryptococcosis, lack of efficacy and off-label use: case report
Reactions Weekly, 2022, 1923 (1) : 49 - 49
[4] AntineoplasticsEpendymosarcoma, lack of efficacy and off-label use: case report
Reactions Weekly, 2020, 1833 (1) : 50 - 50
[5] AntineoplasticsVarious toxicities, lack of efficacy and off-label use: case report
Reactions Weekly, 2023, 1939 (1) : 63 - 63
[6] Multiple drugsNeutropenia, lack of efficacy and off-label use: case report
Reactions Weekly, 2021, 1836 (1) : 546 - 546
[7] Multiple drugsThrombocytopenia, off-label use and lack of efficacy: case report
Reactions Weekly, 2023, 1984 (1) : 376 - 376
[8] AntineoplasticsVarious toxicities, lack of efficacy and off-label use: case report
Reactions Weekly, 2022, 1931 (1) : 86 - 86
[9] AntineoplasticsPneumonia following off-label use and lack of efficacy: case report
Reactions Weekly, 2022, 1936 (1) : 69 - 69
[10] Multiple drugsFever, off-label use and lack of efficacy: case report
Reactions Weekly, 2020, 1815 (1) : 216 - 216

← 1 2 3 4 5 →